Pediatric Dermatology

At MOPD 2026, Nanette Silverberg, MD, and Lisa Swanson, MD, unpack teen AD, fragrance allergy, and social media skin care hype harming barriers.

MOPD 2026 brings together leading experts to review recent therapeutic advances and practical management strategies in pediatric dermatology.

An educational smartphone app significantly reduced atopic dermatitis relapse in children, enhancing caregiver engagement and timely intervention.

Pediatric atopic dermatitis often leads to allergic comorbidities, increasing treatment needs and health care costs, according to a new Japanese study.

A Winter Clinical Hawaii poster determined that roflumilast cream 0.05% is well tolerated and effective for diverse patient populations with atopic dermatitis

A mother shares her personal journey with her daughter's chronic spontaneous urticaria, highlighting the emotional and treatment challenges faced by families.

A Prescription Drug User Fee Act target action date is set for June 29, 2026.

At the Elevate-Derm Fall Conference, Peter Lio, MD, highlighted practical strategies for corticosteroid stewardship, the expanding role of nonsteroidal topicals, and emerging opportunities in early-age indications that are reshaping pediatric inflammatory dermatoses care.

Arcutis advances pediatric atopic dermatitis treatment with roflumilast cream, completing enrollment in key INTEGUMENT-INFANT trial.

Yasmine Kirkorian, MD, shares insights on pediatric dermatology advancements and genetic skin disorders at SDPA Fall 2025, emphasizing early diagnosis and innovative therapies.

Arcutis has expanded roflumilast cream in the US, a steroid-free treatment for mild to moderate AD in young children.

At Fall Clinical 2025, experts discussed the science behind oral IL-23 inhibition, potentially ending the injection-only era for psoriasis therapy.

Vimal Prajapati, MD, FRCPC, DABD, highlights the durable efficacy of guselkumab, reassuring safety, and quality-of-life improvements in pediatric patients with moderate to severe plaque psoriasis.

The FDA has approved roflumilast 0.05% cream for atopic dermatitis in children aged 2 years and older, extending its use to a critical pediatric population.

Mary W. Chang, MD, discusses the expanded FDA approval of ruxolitinib cream for children with atopic dermatitis and its role in addressing treatment gaps, safety, and real-world use.

Elena Hawryluk, MD, PhD, shares groundbreaking insights on pediatric dermatology and melanoma management at Maui Derm NP+PA, emphasizing innovative treatments.

Discover the latest advancements in pediatric dermatology and atopic dermatitis treatments from Maui Derm NP+PA Fall 2025, featuring expert insights and emerging therapies.

Berdazimer shows promise for treating MC in pediatric patients, even in those with a history of atopic dermatitis, according to a poster at Maui Derm NP+PA Fall.

Nicole Harter, MD, explores ruxolitinib 1.5% cream for pediatric atopic dermatitis, offering a novel, effective treatment option for children aged 2 to 11.

Ruxolitinib cream has become the first topical JAK inhibitor available for pediatric atopic dermatitis (AD) in the US.

Experts discuss innovative topical therapies for pediatric AD, emphasizing individualized treatment and the importance of managing itch and sleep quality.

Arcutis Biotherapeutics seeks FDA approval for Zoryve cream to treat plaque psoriasis in children as young as 2, addressing a critical treatment gap.

Lisa Swanson, MD, FAAD, shares innovative insights on pediatric dermatology, emphasizing effective treatments and communication strategies for young patients at DERM 2025.

Explore common pediatric summer skin issues, from rashes to sun sensitivity, and learn effective prevention and management strategies for healthy skin.

Walter Liszewski, MD, shares expert strategies for managing body surface area limitations in AD treatment using non-steroidal topicals, and explored key unmet needs in the current therapeutic landscape.